Drugs / Aldoxorubicin
Aldoxorubicin
also known as
Aldoxorubicin HCl · INNO-206 · Aldoxorubicin Hydrochloride · Aldoxorubicina · Aldoxorubicine · DOXO-EMCH · Doxorubicin-emch · INNO-206 HYDROCHLORIDE
Small molecule targets TOP2A via inhibition
Trials 23 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02235688 | Aug 2014 → Jan 2017 | metastatic neoplasm | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01706835 | Oct 2012 → Dec 2014 | cancer | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01673438 | Jul 2012 → Apr 2014 | neoplasm | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01337505 | Apr 2011 → Sep 2012 | cancer | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT03563157 | Sep 2018 → Apr 2019 | colorectal cancer | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03647423 | Aug 2018 → Aug 2020 | chordoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03586869 | Jul 2018 → Apr 2019 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03563170 | May 2018 → Aug 2019 | hepatocellular carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03387111 | Jan 2018 → Apr 2019 | squamous cell carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03387098 | Dec 2017 → Sep 2018 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02235701 | Sep 2014 → May 2018 | soft tissue sarcoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT04390399 | Jul 2020 → Oct 2025 overdue | malignant pancreatic neoplasm | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03554109 | Sep 2018 → Jun 2020 | triple-negative breast carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03563144 | Aug 2018 → Dec 2019 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03574649 | Jun → Aug 2018 | non-small cell lung carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02200757 | Apr 2015 → May 2017 | small cell lung carcinoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02029430 | Apr 2014 → Apr 2016 | AIDS, Kaposi's sarcoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02014844 | Mar 2014 → Dec 2016 | glioblastoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01580397 | May 2012 → May 2013 | pancreatic ductal adenocarcinoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01514188 | Jan 2012 → Apr 2014 | soft tissue sarcoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00472771 | May → Nov 2008 | small cell lung carcinoma | CytRx | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02049905 | Jan 2014 → May 2017 | soft tissue sarcoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02570412 | — | sarcoma | CytRx | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03387085 Background | Mar 2018 → Sep 2020 | triple-negative breast carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aldoxorubicin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03563170 ↗ |
| Known as | Aldoxorubicin HCl | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03554109 ↗ |
| Known as | Aldoxorubicin Hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03647423 ↗ |
| Known as | Aldoxorubicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107818 ↗ |
| Known as | Aldoxorubicine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107818 ↗ |
| Known as | DOXO-EMCH | “Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors” NCT01706835 ↗ |
| Known as | Doxorubicin-emch | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107818 ↗ |
| Known as | INNO-206 | “INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles” NCT01514188 ↗ |
| Known as | INNO-206 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107818 ↗ |
| Action | Inhibit | “DNA topoisomerase II alpha inhibitor” CHEMBL2107818 ↗ |
| Modality | Small molecule | “Albumin-binding prodrug of doxorubicin HCl” NCT03563144 ↗ |
| Route | Intravenous | “through intravenous infusion” NCT01337505 ↗ |
| Target | TOP2A | “DNA topoisomerase II alpha inhibitor” CHEMBL2107818 ↗ |